A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
This trial is active, not recruiting.
|Start date||May 2013|
|End date||September 2016|
|Trial size||40 participants|
|Trial identifier||NCT01864538, TH-CR-413|
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Los Angeles, CA||The Angeles Clinic and Research Institute||no longer recruiting|
|Los Angeles, CA||UCLA / Jonsson Comprehensive Cancer Center||no longer recruiting|
|Los Angeles, CA||UCLA||no longer recruiting|
|New York, NY||Columbia University / Herbert Irving Cancer Center||terminated|
|Edmonton, Canada||Cross Cancer Institute||no longer recruiting|
|Hamilton, Canada||Juravinski Cancer Centre||no longer recruiting|
|London, Canada||London Health Sciences Centre||no longer recruiting|
|Toronto, Canada||Princess Margaret Hospital||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
time frame: 2 years
Identify potential imaging, serum, and tissue biomarker(s) that predict for response and toxicities to TH-302.
time frame: 2 years
Incidence and severity of adverse events associated with TH-302.
time frame: 2 years
Male or female participants at least 18 years old.
Inclusion Criteria: 1. At least 18 years of age 2. Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's Regional Ethics Board/Independent Ethics Committee (REB/IEC) 3. Histologically documented cutaneous or mucosal malignant melanoma, which is recurrent or metastatic and is not curable by surgical or other means. 4. Adequate tumour tissue (greater than 0.5cm3 preferred, 3 X core biopsy acceptable) available and agreement from subjects that this tissue from their primary and/or metastatic tumour be made available for assessment of potential biomarkers. 5. Ability and availability to complete all prescribed biomarker studies (Screening and after Cycle 2). 6. Recovered to Grade 1 from reversible toxicities of prior therapy 7. Presence of clinically and/or radiologically documented disease. At least one site of disease (which will not be removed during the course of the study) must be uni-dimensionally measurable as per RECIST 1.1 or clinically quantifiable (such as in the case of skin disease) 8. ECOG performance status of 0 - 1. 9. Prior treatment with any number of immunotherapies (e.g., IL2, ipilimumab), targeted therapies (e.g., vemurafenib) are permitted but no more than one 1 prior chemotherapy 10. Acceptable liver function 11. Acceptable renal function 12. Acceptable hematologic status (without growth factor support for neutropenia or transfusion dependency): 13. Normal 12-lead ECG (clinically insignificant abnormalities permitted) 14. Female subjects of childbearing age must have a negative urine HCG test unless prior hysterectomy or menopause (defined as age above 55 and twelve months without menstrual activity). Female subjects should not become pregnant or breast-feed while on this study. Sexually active male and female subjects should use effective birth control. Exclusion Criteria: 1. Anticancer treatment with radiation therapy, targeted therapies, chemotherapy, immunotherapy, hormones or other antitumour therapies within 28 days prior to first dose of TH-302. 2. Subjects who have received any other investigational drug or agent within 28 days of first dose of TH-302 3. Current use of drugs with known cardiotoxicity 4. Significant cardiac dysfunction: 5. Seizure disorders requiring anticonvulsant therapy 6. Progressing brain metastases (unless previously treated and stable disease for a period of greater than or equal to 3 months on repeat MRI following definitive treatment). 7. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for greater than 2 years 8. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation less than 90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause hypoxia of normal tissue. 9. Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery 10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy 11. Prior therapy with an hypoxic cytotoxin 12. Known infection with HIV or active infection with hepatitis B or hepatitis C 13. History of allergic reaction to a structural compound or biological agent similar to TH-302 14. Pregnancy or breast-feeding 15. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study 16. Unwillingness or inability to comply with the study protocol for any reason.
|Official title||A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma|
|Description||Hypoxia is an independent marker of a poor prognosis for subjects with metastatic melanoma (Simonetti 2012, Lartigau 1997). Hypoxic melanoma cells are more likely to exhibit a stem-cell like phenotype with an associated increased propensity for invasion, angiogenesis, and metastasis formation compared to normoxic cells. Moreover, this phenotype is also associated with treatment resistance. TH-302, a hypoxia activated prodrug (HAP), was designed to target the hypoxic nature of tumours while having a minimal effect on normoxic tissue. TH-302 belongs to a class of alkylating agents that have significant experimental and clinical activity (Brock 1989). Preclinical data support the hypothesis that TH-302 targets hypoxic regions of tumours and is also able to kill tumour cells in normoxic regions as a result of cytotoxin diffusion, leading to significant effects on tumour growth (Meng 2011). TH-302 has been investigated in over 700 subjects with solid tumours or hematologic malignancies, including subjects with metastatic melanoma. In this subset a disease control rate of 63% (3 subjects with partial responses and 9 subjects with stable disease out of a total of 19) was observed in an early phase clinical trial of TH-302 (Weber 2010). Predictive biomarkers for response and toxicity have yet to be identified for subjects with advanced melanoma treated with TH-302. Optimal patient selection may be critical to maximize the clinical benefit. A predictive biomarker approach will be investigated to try to identify subjects most likely to benefit from TH-302. Given the hypoxia-targeting mechanism of TH- 302, it is believed that hypoxia biomarkers will be the most informative for identifying subjects likely to benefit from TH- 302; however, additional biomarkers including DNA repair biomarkers will also be investigated. In addition, this approach will also have potential to synergise with future immunotherapeutic approaches as suppressive T regulatory cells are thought to reside within hypoxic niches within the tumour microenvironment that would be amenable to targeting by TH-302.|
Call for more information